Kornimate/medical-research-clean huggingface dataset:
evaluation of the effect of fertility support education given to infertile couples

Conditions: Infertility

Summary: the aim of the this study was to evaluate the effect of fertility support education given to infertile couples before treatment.

before the treatment, couples were given fertility support training for four weeks. after the treatment was completed, the couples' stress level and quality of life, women's self-efficacy, fertility readiness, cortisol levels and pregnancy outcomes were examined.

Eligibility criteria:
inclusion criteria: * diagnosed with primary infertility * have not received fertility support training before * can speak turkish exclusion criteria: * with psychiatric illness

Keywords: stress cortisol level pregnancy outcome infertility
efficacy of computer-assisted cognitive remediation in patients with schizophrenia

Conditions: Schizophrenia; Psychosis; Cognitive Impairment; Executive Function; Randomized Controlled Trial; Efficacy

Summary: objective: to determine the efficacy of computer-assisted cognitive remediation (cacr) in patients with chronic schizophrenia in the community settings. study design: single-blinded prospective, pre-test/post-test randomized controlled trial (rct) will be conducted in 2 groups of participants that receiving training in community settings. treatment groups will attend individualized cacr programme using cogniplus® while control group will continue attend conventional treatment as usual (tau). assessment on the means difference in assessing functions will be done after the study. samples: 80 patients with stable and chronic schizophrenia will be recruited from the community, using a sampling frame of selected diagnosis and homogeneity. expected findings: find out the training effects of selected cacr on ef and daily functioning in patients with schizophrenia.

schizophrenia is one of the most serious and disabling mental disorders. prevalence of schizophrenia is about 1% worldwide. the related dysfunctions have great impact and burden to the concerned person and to the society. with increasing use of cr programmes in helping the patients to resume their capability in community living, the clinical outcome was not fully established especially on specific cognitive domains such as executive function (ef). the present study aims at evaluating the efficacy of cacr on developing ef and improving daily functioning. the result will provide information for therapists' future clinical decisions for patients' best reintegration into the societies. this also helps decrease the burden of family, society in the long run.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia, based on diagnostic and statistical manual of mental disorders (5th ed.), at chronic and stable state * age from 18 to 64 * regular attendance to rehabilitation training programmes * willing and capable to participate and are voluntarily consent to the participation * pass the cut-off point of referenced screening tests exclusion criteria: * comorbid differential diagnosis * history of organic brain disorder * complicated conditions that preclude regular attendance of the training * currently receiving computer-assisted cognitive remediation and other individual intensive cognitive training

Keywords: randomized controlled trial computer-assisted cognitive remediation executive function
redetachment under densiron for rd multiple breaks

Conditions: Retinal Detachment Multiple Breaks

Summary: densiron is used as a tamponading agent for inferior retinal detachment with inferior retinal breaks however, data about the use of densiron -68 for rrd with multiple retinal breaks; especially if involving both superior and inferior quadrants; are not sufficient.

inferior retinal detachment (ird) (retinal detachment with inferior retinal breaks ± proliferative vitreoretinopathy) poses a challenge to primary pars plana vitrectomy because of the insufficient tamponade effect. lighter than water tamponading agents - including gas and silicone oil (so)- provide no contact with inferior retina, which may open up inferior retinal breaks and may develop proliferative vitreoretinopathy (pvr) as well. heavier than water tamponading agents are used for ird with a favorable outcome. they include: fluorosilicone oil (fso) 1 2, perfluorocarbon liquids 3 4 , semifluorinated alkanes namely perfluorhexyloctane (f6h8) 5, and fluorinated alkanes which include: heavysil 6, oxane hd 7 8 9 10, hws 46-3000 11, and densiron-68. 12-22 densiron-68 (fluoron, neu ulm, germany) consists of a mixture of polydimethylsiloxane 5000 (pdms) (69.5%) and perfluorhexyloctane (h6f8) (30.5%). it has a viscosity of 1387 mpas, specific gravity of 1.06 g/cm3, and interfacial tension of 35 mn/m. it has been successfully employed for ird with a favorable outcome. 15,17,19,20,22,16,12-14,23,18 the final retinal reattachment rate reached up to 95%. 15 there are several reports about the use of densiron-68 for ird associated with pvr which reveal a favorable secondary reattachment rate; ranging between 70% and 95%. 17,21,24,25 however, data about the use of densiron -68 for rrd with multiple retinal breaks; especially if involving both superior and inferior quadrants; are not sufficient.

Eligibility criteria:
inclusion criteria: * - rrd with multiple retinal breaks (mrbs), using densiron-68 tamponade. * age= 16 and older exclusion criteria: * - rrd using conventional silicone oil (so) or gas tamponade. * rrd with single rbs * age \< 16 years
68ga-ny104 pet/ct in patients with metastatic clear cell renal cell carcinoma

Conditions: Metastatic Clear Cell Renal Cell Carcinoma

Summary: this is a prospective, single-center, single-arm, comparative phase 2 study in patients with metastatic clear cell renal cell carcinoma. the goal is to determine the sensitivity of 68ga-ny104 pet/ct in patients with metastatic clear cell renal cell carcinoma and compare it with 18f-fdg pet/ct.

this is a prospective, single-center, single-arm, comparative phase 2 study in patients with metastatic clear cell renal cell carcinoma. each patient will receive one dose of 68ga-ny104 and one dose of 18f-fdg by intravenous route. dedicated whole-body pet/ct imaging will be performed. pet/ct studies will be interpreted by two readers, both of whom will provide independent, blinded interpretations. imaging interpretations and a composite reference standard will be used to estimate the sensitivity of each modality. the tumor uptake will also be compared for matched lesions. 39 patients will be recruited in peking union medical college hospital.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 y 2. histopathological diagnosis of clear cell renal cell carcinoma 3. metastatic disease confirmed by histopathology or typical appearance of multifocal metastatic disease 4. expected survival of at least 6 months 5. ecog ≤ 2 6. written informed consent provided for participation in the trial 7. in the opinion of investigator, willing and able to comply with required study procedures. exclusion criteria: 1. on vegf tki treatment less than 1 week before 68ga-ny104 pet/ct. tki is known to affect girentuximab binding in patients with ccrcc and is expected to have the same effect on 68ga-ny104. if patients were on vegf tki treatment, such as sunitinib, sorafenib, cabozantinib, pazopanib, or lenvatinib, a washout of one week before 68ga-ny104 pet/ct is required. 2. patients on hif antagonist treatment \< 3 months before 68ga-ny104 pet/ct. ca9, which encodes carbonic anhydrase ix (caix), is one of the genes most strongly upregulated by hif-1. hif antagonist, such as belzutifan, might affect the expression of caix and thus the binding of 68ga-ny104 to tumor. withdraw of at least 3 months is required for hif antagonist. 3. pregnancy or breastfeeding. 4. severe claustrophobia.

Keywords: 68ga-ny104 pet/ct clear cell renal cell carcinoma
acamprosate: genes associated with response

Conditions: Alcoholism

Summary: in 2004, acamprosate was approved in the u.s. for abstinence maintenance, by decreasing craving, in alcoholic patients who have undergone detoxification. while a new anti-craving drug was encouraging, only 36.1% of the subjects treated with acamprosate remained abstinent for 6 months. having the ability to identify treatment responsive individuals would have a major impact on the use of acamprosate.

the primary objective of this pharmacogenomic probe study of acamprosate is to identify genetic variations that predict response. our hypothesis is that effective acamprosate response in alcohol dependent subjects may be influenced by genetically controlled variation in the functionality of the n-methyl-d-aspartate receptor (nmda) and/or the type 5 metabotropic glutamate receptor (mglur5). hypothesis confirmation could lead to development of effective individualized treatment recommendations for alcohol dependent patients based on pharmacogenomically relevant genetic variations. the general goal is to identify genetic polymorphic variants that differentiate subjects continuously abstinent for six months while taking acamprosate from relapsed subjects. the initial analysis will determine whether any of ten polymorphisms in four target genes (grin1, grin2a and grin2b that code for the nmda receptor and grm5 that codes for the type mglur5 receptor) are associated with successful abstinence. subsequent analyses will examine whether variation in a comprehensive set of 383 linkage disequilibrium haplotype tagged single nucleotide polymorphisms of these four genes predicts successfully abstinent subjects.

Eligibility criteria:
inclusion criteria: 1. male or females, age 18-80. 2. 2. primary diagnosis of alcohol dependence based on dsm-iv-tr criteria and determined by the psychiatric research interview for substance and mental disorders (prism) (stable mood and anxiety disorders will not be exclusionary). 3. prior enrollment in the irb approved protocol "developing a dna repository for genomic studies of addiction: a pilot study". exclusion criteria: 1. inability to provide informed consent. 2. inability to speak english. 3. history of hypersensitivity or allergic reaction to acamprosate. 4. moderate to severe renal impairment, as determined by a creatinine level \> 1.5 mg/dl. 5. diagnosis of primary biliary cirrhosis, chronic active hepatitis, and drug-induced hepatic insufficiency, as noted in the medical record. 6. women who are pregnant, lactating, or are planning to become pregnant during the next year. 7. any unstable active medical or additional psychiatric condition as determined by the investigator. 9. active suicidal ideation as determined by responses provided during prism or as determined by the investigator.

Keywords: nucleotide polymorphisms disequilibrium haplotype acamprosate differentiate pharmacogenomic effective individualized treatment alcohol dependent n-methyl-d-aspartate receptor (nmda) metabotropic glutamate receptor decreasing craving abstinence maintenance
natural history study of patients with hpdl mutations

Conditions: Mitochondrial Encephalomyopathies; Hereditary Spastic Paraplegia; Spastic Paraplegia; White Matter Disease; Neonatal Encephalopathy; Mutation; Genetic Disease

Summary: this study uses medical records that allow retrospective data extraction of clinical manifestation to assess the natural history of hpdl mutations

a novel mitochondrial disease arises from mutations in hpdl, which codes for 4-hydroxyphenylpyruvate dioxygenase-like protein. the main purpose of this study is to establish a patient registry to gather medical data from consenting hpdl mutation patients worldwide. from longitudinal data, we will be able to figure out the natural history of the disease, and genotype-phenotype correlation. dry blood spots will be collected to develop biomarkers to understand the disease better.

Eligibility criteria:
inclusion criteria: * any individuals diagnosed with hpdl variants * clinical diagnosis can include: * hpdl-related hereditary spastic paraplegia (hsp) * hpdl-related neonatal mitochondrial encephalopathy * spastic paraplegia -83 (spg83) * neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities (nedswma) exclusion criteria: * any known genetic abnormality (other than hpdl mutation) * any condition that, in the opinion of the site investigator, could put the participant at undue risk and/or would ultimately prevent the completion of study procedures

Keywords: hpdl hpdl related neonatal mitochondrial encephalopathy hpdl related hereditary spastic paraplegia spastic paraplegia-83 neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities
prospective multiple myeloma impact study

Conditions: Multiple Myeloma

Summary: this will be a prospective, case-only, study to measure the impact of mmprofiler on treatment intention decisions in multiple myeloma patients.

this will be a prospective, case-only, study to measure the impact of mmprofiler on treatment intention decisions in mm patients. eligible patients will have their tumor sample analyzed for the prognostic mmprofiler sky92, several cytogenetic markers, gene expression markers, and gene expression clusters. a total of 250 patients will be enrolled from up to 9 us centers. patients will be followed 5 years after diagnosis.

Eligibility criteria:
inclusion criteria: * potentially multiple myeloma according to imwg criteria * candidates for systemic treatment exclusion criteria: * ecog performance status \> 3 * tumor sample that fails qa or qc criteria for mmprofiler
clinical outcome of palliative surgery after translational therapy for metastatic gastric cancer versus maintenance chemotherapy for metastatic gastric cancer

Conditions: Metastatic Gastric Cancer; Surgery; Chemotherapy

Summary: this single-center, prospective study was conducted to investigate the efficacy and safety of palliative surgery after translational therapy in the treatment of metastatic gastric cancer. the primary endpoint was 2-year overall survival (os) rate. secondary endpoints were median os, progression-free survival (pfs), 1-year os, adverse events (ae), severe ae, the quality of life (qol) and treatment cost.


Eligibility criteria:
inclusion criteria: * age from 18 to 75 years * primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically * ct/mri, pet-ct, or laparoscopic exploration should be performed before surgery to confirm the diagnosis of distant metastasis * performance status of 0 or 1 on eastern cooperative oncology group scale (ecog) * estimated survival time was over 3 months * the major organs are functioning normally and meet the following criteria: (1) blood routine examination should meet the requirements (no blood transfusion within 14 days): 1. hb≥100g/l， 2. wbc≥3×109/l 3. anc≥1.5×109/l， 4. plt≥100×109/l； （2）biochemical tests must meet the following criteria： 1. bil \<1.5×upper limit of normal (uln)， 2. alt and ast\<2.5uln，gpt≤1.5×uln； 3. cr≤1uln，ccr \>60ml/min * fertile women must have taken a pregnancy test (serum) within 7 days prior to enrollment with negative results and be willing to use an appropriate method of contraception during the trial period and 8 weeks after the last trial drug; for men, they should be surgically sterilized or agree to use the appropriate method of contraception during the trial period and 8 weeks after the last administration of the trial drug * did not participate in other clinical studies before and during treatment * subjects voluntarily joined the study and signed informed consent with good compliance and follow-up exclusion criteria: * history of other malignant disease within past five years * history of immunodeficiency, including hiv positive, or other acquired congenital immunodeficiency disease, or a history of organ transplantation and allogeneic bone marrow transplantation * accompanied by serious heart, lung, liver and kidney diseases, neuropsychiatric disorders, jaundice or associated severe infection * women during pregnancy or breast-feeding * subjects had poorly controlled cardiovascular clinical symptoms or diseases, including but not limited to: 1. nyha class ii or more serious heart failure 2. unstable angina pectoris 3. myocardial infarction within 1 year 4. clinically significant ventricular or ventricular arrhythmias that were poorly controlled without or despite clinical intervention
the copper t380a iud vs. oral levonorgestrel for emergency contraception

Conditions: Pregnancy

Summary: the purpose of this study is to see if women presenting for emergency contraception (ec) and choose the copper intrauterine device (iud) will have fewer unplanned pregnancies in the next year compared to women who choose oral levonorgestrel for ec. the study will also compare use of an effective method of contraception in the year after they received ec.

all women presenting to 2 planned parenthood association of utah clinics in salt lake city will be offered participation in this study. women will select either the copper iud or oral levonorgestrel for ec. the primary outcome is unplanned pregnancy in the year following presentation for ec. secondary outcomes include use of an effective method of contraception over the next year, abortions, repeat use of ec, number of days to first bleeding episode and duration of that bleeding episode, use of a barrier method to prevent sexually transmitted infections, patient satisfaction with the chosen method of ec and contraception. participants selecting the iud will be assessed for iud expulsion, perforation, and removal.

Eligibility criteria:
inclusion criteria: * women 18-30 years old, * in need of emergency contraception (had unprotected intercourse within 120 hours), * willing to give consent for participation in research, * willing to comply with study requirements, and * accessible by telephone. participants selecting the iud need to identify themselves as desiring long-term contraception. exclusion criteria: * current pregnancy * had pelvic inflammatory disease or septic abortion within the past 3 months or had gonorrhea or chlamydia infection in the last 60 days * current behavior suggesting a high risk for pelvic inflammatory disease * allergy to copper or wilson's disease (for participants selecting the copper iud) or allergy to levonorgestrel (for participants selecting oral levonorgestrel) * abnormalities of the uterus that distort the uterine cavity * mucopurulent cervicitis * a previously placed iud that has not been removed * genital bleeding of an unknown etiology * ovarian, cervical, or endometrial cancer * small uterine cavity (\< 6cm)

Keywords: contraception emergency contraception pregnancy prevention after unprotected intercourse
surface ablation with corneal cross linking in mild keratoconus

Conditions: Keratoconus; Corneal Cross-Linking

Summary: interventional and comparative prospective study: sixty-nine eyes (38 patients) suffering from keratoconus (stages 1-2 amsler-krumeich classification) will be divided into four groups. the four groups underwent topography- and non-topography-guided prk with sequential and simultaneous cxl. the main outcome measures will be pre-and postoperative uncorrected distance visual acuity (udva), best-corrected distance visual acuity (cdva), manifest refraction, contrast sensitivity, and keratometry


Eligibility criteria:
inclusion criteria for the study focused on patients over 34 (range from 34 to 41) with stable corneal topography and refraction for at least six months and an estimated residual bed thickness of \>410 µm. exclusion from the study included the presence of macular or retinal disease, dry eye, history of recurrent corneal erosions, anterior segment abnormalities, unstable refractive error, post-surgically residual stromal bed thickness of under 350 mm, autoimmune disease, collagen vascular disease, immunosuppressive therapy, or current use of systemic corticosteroids, diabetes mellitus, pregnancy, and lactation.
eingeschränkte vs ausgedehnte lymphadenektomie lea

Conditions: Bladder Cancer

Summary: this trial evaluates the therapeutic benefit of extended versus limited lymphadenectomy at the time of radical cystectomy in patients with bladder cancer.

the extent of pelvic lymphadenectomy in the surgical treatment of muscle-invasive, clinically locally bladder cancer is not yet standardized. there are no data from randomized, prospective studies on the prognostic role of regional lymphadenectomy. results of retrospective studies suggest, that the prognosis of patients with muscle-invasive bladder cancer can be improved by extending the limits of pelvic lymphadenectomy. furthermore it could be demonstrated in a prospective study that the pattern of metastasis of bladder cancer has a high variability. about two-thirds of lymph node metastases are found outside the normally cleared areas of lymphadenectomy. in this study patients will be randomized into arms with limited versus extended lymphadenectomy. the limited lymphadenectomy includes the removal of the obturatoric, external and internal iliac lymph nodes, the extended one includes the removal of all lymph nodes between pelvic floor and the inferior mesenteric artery. the primary objective of the study is to detemine the influence of limited versus extended lyphadenectomy at the time of radical cystectomy on recurrence-free survival. secondary study objectives include the influence on cancer-specific survival, overall survival, complication rates, histopathologic n-stage, the localization of recurrence and influence of adjuvant chemotherapy . adjuvant chemotherapy is optional and is recommended in patients with locally advanced disease (pt3/4) or regional lymph node metastasis (pn+).

Eligibility criteria:
inclusion criteria: * histologically proven, invasive urothelial bladder cancer, locally completely resectable (t1g3 - t4a, nx) * age \>= 18 years * written consent of the patient * patient compliance and geographic proximity to allow adequate follow-up exclusion criteria: * histologically or by imaging diagnostics proven organ metastases * radiographic evidence of enlarged lymph nodes (\> 1 cm) above the aortic bifurcation in conjunction with pelvic lymph node metastases * radiographic or other evidence of t4b-tumor (infiltration of the pelvic wall or other organ systems) * prior neoadjuvant chemotherapy of bladder cancer * prior previous pelvic lymphadenectomy * prior radiotherapy to the pelvis * internal medical or anesthetic risk factors that require a short operation time * palliative cystectomy (f.e. bulky-disease, infiltration of adjacent structures) * evidence of another tumor restricting life expectancy of the patient

Keywords: lymphadenectomy extension bladder cancer